Literature DB >> 24081122

Panorama from the oncolytic virotherapy summit.

Jonathan G Pol1, Monique Marguerie, Rozanne Arulanandam, John C Bell, Brian D Lichty.   

Abstract

Mesh：

Year:  2013        PMID： 24081122      PMCID： PMC3808141          DOI： 10.1038/mt.2013.207

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  39 in total

Review 1.  Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus.

Authors:  Masmudur M Rahman; Gerard J Madlambayan; Christopher R Cogle; Grant McFadden
Journal:  Cytokine Growth Factor Rev       Date:  2010-03-07       Impact factor: 7.638

2.  Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells.

Authors:  Yupei Zhao; Songjie Shen; Junchao Guo; Herbert Chen; David Yu Greenblatt; Jörg Kleeff; Quan Liao; Ge Chen; Helmut Friess; Po Sing Leung
Journal:  J Surg Res       Date:  2006-10-19       Impact factor: 2.192

3.  Synergistic interaction between oncolytic viruses augments tumor killing.

Authors:  Fabrice Le Boeuf; Jean-Simon Diallo; J Andrea McCart; Steve Thorne; Theresa Falls; Marianne Stanford; Femina Kanji; Rebecca Auer; Christopher W Brown; Brian D Lichty; Kelley Parato; Harold Atkins; David Kirn; John C Bell
Journal:  Mol Ther       Date:  2010-03-16       Impact factor: 11.454

4.  Potentiating cancer immunotherapy using an oncolytic virus.

Authors:  Byram W Bridle; Kyle B Stephenson; Jeanette E Boudreau; Sandeep Koshy; Natasha Kazdhan; Eleanor Pullenayegum; Jérôme Brunellière; Jonathan L Bramson; Brian D Lichty; Yonghong Wan
Journal:  Mol Ther       Date:  2010-06-15       Impact factor: 11.454

5.  The 67 kDa laminin receptor increases tumor aggressiveness by remodeling laminin-1.

Authors:  V Berno; D Porrini; F Castiglioni; M Campiglio; P Casalini; S M Pupa; A Balsari; S Ménard; E Tagliabue
Journal:  Endocr Relat Cancer       Date:  2005-06       Impact factor: 5.678

6.  Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21.

Authors:  Darren R Shafren; Gough G Au; Tam Nguyen; Nicole G Newcombe; Erin S Haley; Leone Beagley; E Susanne Johansson; Peter Hersey; Richard D Barry
Journal:  Clin Cancer Res       Date:  2004-01-01       Impact factor: 12.531

7.  Tumor vascularization is critical for oncolytic vaccinia virus treatment of peritoneal carcinomatosis.

Authors:  Kathryn Ottolino-Perry; Nan Tang; Renee Head; Calvin Ng; Rozanne Arulanandam; Fernando A Angarita; Sergio A Acuna; Yonghong Chen; John Bell; Ralph S Dacosta; J Andrea McCart
Journal:  Int J Cancer       Date:  2013-08-29       Impact factor: 7.396

8.  Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication.

Authors:  Robin J Prestwich; Elizabeth J Ilett; Fiona Errington; Rosa M Diaz; Lynette P Steele; Tim Kottke; Jill Thompson; Feorillo Galivo; Kevin J Harrington; Hardev S Pandha; Peter J Selby; Richard G Vile; Alan A Melcher
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

9.  Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.

Authors:  Shanthi Ganesh; Melissa Gonzalez-Edick; Douglas Gibbons; Melinda Van Roey; Karin Jooss
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

10.  Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells.

Authors:  M Kim; G J Madlambayan; M M Rahman; S E Smallwood; A M Meacham; K Hosaka; E W Scott; C R Cogle; G McFadden
Journal:  Leukemia       Date:  2009-10-29       Impact factor: 11.528
View more
  6 in total

Review 1.  Oncolytic Virotherapy for the Treatment of Malignant Glioma.

Authors:  Paul M Foreman; Gregory K Friedman; Kevin A Cassady; James M Markert
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

Review 2.  Glioblastoma antigen discovery--foundations for immunotherapy.

Authors:  Tej D Azad; Seyed-Mostafa Razavi; Benjamin Jin; Karen Lee; Gordon Li
Journal:  J Neurooncol       Date:  2015-06-05       Impact factor: 4.130

3.  ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models.

Authors:  Wenliang Dong; Jan-Willem H van Ginkel; Kam Y Au; Ramon Alemany; Janneke J M Meulenberg; Victor W van Beusechem
Journal:  Hum Gene Ther       Date:  2014-09-17       Impact factor: 5.695

Review 4.  Glioma virus therapies between bench and bedside.

Authors:  Johanna K Kaufmann; E Antonio Chiocca
Journal:  Neuro Oncol       Date:  2014-01-26       Impact factor: 12.300

Review 5.  Emerging treatment strategies for glioblastoma multiforme.

Authors:  Steven K Carlsson; Shaun P Brothers; Claes Wahlestedt
Journal:  EMBO Mol Med       Date:  2014-11       Impact factor: 12.137

Review 6.  Trial Watch:: Oncolytic viruses for cancer therapy.

Authors:  Jonathan Pol; Norma Bloy; Florine Obrist; Alexander Eggermont; Jérôme Galon; Isabelle Cremer; Philippe Erbs; Jean-Marc Limacher; Xavier Preville; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-06-01       Impact factor: 8.110
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.